Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML8M3B)

Drug Name
LY-2584702 Drug Info
Synonyms LY-S6K1; LY-S6K1 HCl; LY-S6K1 tosylate; P70 S6 kinase inhibitor (cancer), Eli Lilly
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
25118925
CAS Number
CAS 1082949-67-4
TTD Drug ID
DML8M3B

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Ribosomal protein S6 kinase (S6K)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LYS-6KAKT1 DMLXGAI Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
LY2780301 DM93AJW Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
XL418 DME0F5W Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PMID27410995-Compound-Figure3k DMJ0QLB N. A. N. A. Patented [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ribosomal protein S6 kinase (S6K) TT7M3PI NOUNIPROTAC Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8248).
2 A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84.
3 DOI: 10.1016/S1359-6349(10)71767-5
4 A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
5 Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
6 Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.